viernes, 29 de marzo de 2019

From genome integrity to cancer

From genome integrity to cancer



From genome integrity to cancer

Guest editor: Dr Serena Nik-Zainal

New Content Item
Genome Medicine is pleased to present a special issue entitled ‘From genome integrity to cancer: mechanisms and translational opportunities’. Next-generation sequencing and genomic approaches are revealing the mechanisms underlying genome integrity and how they are compromised in age-related diseases and cancer; this information can guide precision medicine. This issue captures the advances in understanding mutational processes and signatures, genome instability, cancer evolution, tumor heterogeneity, immune escape and resistance to therapies.
This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. The Guest Editor declares that they have no competing interests. The Guest Editor serves an advisory role to guide the scope of the special issue and commissioned content; final editorial decisions lie with the Editor.
  2. Content Type:Research

    Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, ...
    Authors:Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H. Adomat, Dong Lin, Hui Xue, Xin Dong, Robert Shukin, Robert H. Bell, Brian McConeghy, Anne Haegert, Sonal Brahmbhatt, Estelle Li…
    Citation:Genome Medicine 2019 11:8
    Published on: 
    The Research Highlight to this article has been published in Genome Medicine 2019 11:18
  4. Content Type:Method

    Circulating tumour DNA (ctDNA) detection and monitoring have enormous potential clinical utility in oncology. We describe here a fast, flexible and cost-effective method to profile multiple genes simultaneousl...
    Authors:Meiling Gao, Maurizio Callari, Emma Beddowes, Stephen-John Sammut, Marta Grzelak, Heather Biggs, Linda Jones, Abdelhamid Boumertit, Sabine C. Linn, Javier Cortes, Mafalda Oliveira, Richard Baird, Suet-Feung Chin and Carlos Caldas
    Citation:Genome Medicine 2019 11:1
    Published on: 
  6. Content Type:Research

    Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resist...
    Authors:Maki Tanioka, Kevin R. Mott, Daniel P. Hollern, Cheng Fan, David B. Darr and Charles M. Perou
    Citation:Genome Medicine 2018 10:86
    Published on: 
  7. Content Type:Review

    Immune checkpoint blockade (ICB) therapies, which potentiate the body’s natural immune response against tumor cells, have shown immense promise in the treatment of various cancers. Currently, tumor mutational ...
    Authors:Jake R. Conway, Eric Kofman, Shirley S. Mo, Haitham Elmarakeby and Eliezer Van Allen
    Citation:Genome Medicine 2018 10:93
    Published on: 
  8. Content Type:Research

    Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its ...
    Authors:Elen Kristine Höglander, Silje Nord, David C. Wedge, Ole Christian Lingjærde, Laxmi Silwal-Pandit, Hedda vdL Gythfeldt, Hans Kristian Moen Vollan, Thomas Fleischer, Marit Krohn, Ellen Schlitchting, Elin Borgen, Øystein Garred, Marit M. Holmen, Erik Wist, Bjørn Naume, Peter Van Loo…
    Citation:Genome Medicine 2018 10:92
    Published on: 
  10. Content Type:Research

    Mutations in KRAS are frequent in human cancer, yet effective targeted therapeutics for these cancers are still lacking. Attempts to drug the MEK kinases downstream of KRAS have had limited success in clinical tr...
    Authors:Tonći Šuštić, Sake van Wageningen, Evert Bosdriesz, Robert J. D. Reid, John Dittmar, Cor Lieftink, Roderick L. Beijersbergen, Lodewyk F. A. Wessels, Rodney Rothstein and René Bernards
    Citation:Genome Medicine 2018 10:90
    Published on: 
  11. Content Type:Comment

    Telomere crisis is linked with many of the genomic alterations found in cancer genomes. A new understanding of how these alterations arise points towards an active role for innate immune sensors during crisis ...
    Authors:Patrick von Morgen and John Maciejowski
    Citation:Genome Medicine 2018 10:89
    Published on: 
  12. Content Type:Comment

    Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinica...
    Authors:J. Bryan Iorgulescu, David Braun, Giacomo Oliveira, Derin B. Keskin and Catherine J. Wu
    Citation:Genome Medicine 2018 10:87
    Published on: 
  13. Content Type:Research

    There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potent...
    Authors:Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey, Lucien Hoekx, Dirk Schrijvers, Barbara Brouwers, Willem Lybaert, Els Everaert, Daan De Maeseneer, Michiel Strijbos, Alain Bols…
    Citation:Genome Medicine 2018 10:85
    Published on: 
  14. Content Type:Research

    Links between colorectal cancer (CRC) and the gut microbiome have been established, but the specific microbial species and their role in carcinogenesis remain an active area of inquiry. Our understanding would...
    Authors:Vanessa L. Hale, Patricio Jeraldo, Jun Chen, Michael Mundy, Janet Yao, Sambhawa Priya, Gary Keeney, Kelly Lyke, Jason Ridlon, Bryan A. White, Amy J. French, Stephen N. Thibodeau, Christian Diener, Osbaldo Resendis-Antonio, Jaime Gransee, Tumpa Dutta…
    Citation:Genome Medicine 2018 10:78
    Published on: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)